Analysis of a safety run-in cohort from NIVEAU, a phase 3 study for patients with aggressive Non-Hodgkin lymphoma in first relapse or progression not eligible for High-Dose Chemotherapy (HDT) testing Nivolumab in combination with (R)-GemOx

L. Thurner,V Poeschel,C. Haioun,R. Houot,P. Gaulard,T. Molina,A. Rosenwald,M. Andre, J. Hoffmann, M. Dreyling,O. Casasnovas, H. Maisonneuve, H. Tilly,T. Illmer,S. Mayer,H. Kirchen,P. La Rosee,M. Loeffler,M. Ziepert,B. Altmann,G. Held

ONCOLOGY RESEARCH AND TREATMENT（2020）

Cited 0|Views81

No score

Abstract

Background: Nivolumab, a human anti-PD1 antibody has the potential to increase rituximab-mediated effector mechanism, to target the microenviroment and PD-1 in aggressive Non-Hodgkin lymphoma. Addition of nivolumab might increase efficacy conventional chemotherapy, which is always combined with rituximab in case of B-cell lymphoma. Therefore, a safety run-in was conducted to determine the tolerability of the combination prior to proceeding with a larger randomized phase 3 study aimed to compare of (R)-GemOx vs. Nivolumab plus (R)-GemOx.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined